MedTrace Logo

Phase II Study of THDBH120 Injection in Overweight or Obese Subjects

NCT07036601 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 276

Last updated 2025-06-25

No results posted yet for this study

Summary

To assess the efficacy and safety of THDBH120 injection compared with placebo in weight reduction in overweight or obese subjects after 26 weeks of treatment.

Conditions

  • Overweight or Obese

Interventions

DRUG

THDBH120 injection

Participants received THDBH120 by subcutaneous injection.

DRUG

Placebo of THDBH120 injection

Participants received placebo by subcutaneous injection.

Sponsors & Collaborators

  • Tonghua Dongbao Pharmaceutical Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-06
Primary Completion
2026-02-13
Completion
2026-03-11

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07036601 on ClinicalTrials.gov